Tellgen(SZ:300642) Sou Hu Cai Jing·2025-05-20 09:38Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongjing Life, which closed at 14.12 yuan with a PE ratio of 58.28, marking a new low in 30 days, and a total market capitalization of 2.302 billion yuan [1] - The company operates in the in vitro diagnostic products sector, focusing on research, production, and sales of its own brand products, including diagnostic reagents and instruments [1] - The latest financial results for Q1 2025 show a revenue of 74.8931 million yuan, a year-on-year decrease of 19.53%, while net profit increased by 110.51% to 471,700 yuan, with a gross margin of 63.66% [1] Group 2 - In terms of industry comparison, the average PE ratio for the medical device sector is 49.51, with a median of 36.17, positioning Tongjing Life at the 92nd rank within the industry [2] - The company has actively engaged in various health-themed public welfare activities and has received multiple awards for its social responsibility efforts, including the "Social Public Welfare Award" from the China Cancer Foundation [1]